Fenazon-Koffein 500 mg / 100 mg Norge - norsk - Statens legemiddelverk

fenazon-koffein 500 mg / 100 mg

orifarm healthcare a/s - fenazon / koffein - tablett - 500 mg / 100 mg

Fenazon-Koffein Sterke 1 g / 100 mg Norge - norsk - Statens legemiddelverk

fenazon-koffein sterke 1 g / 100 mg

orifarm healthcare a/s - fenazon / koffein - tablett - 1 g / 100 mg

Zeldox 80 mg Norge - norsk - Statens legemiddelverk

zeldox 80 mg

pfizer as - ziprasidonhydrokloridmonohydrat - kapsel, hard - 80 mg

Zeldox 20 mg Norge - norsk - Statens legemiddelverk

zeldox 20 mg

pfizer as - ziprasidonhydrokloridmonohydrat - kapsel, hard - 20 mg

Fanalgin 500 mg / 50 mg Norge - norsk - Statens legemiddelverk

fanalgin 500 mg / 50 mg

karo pharma as - fenazon / koffein - tablett - 500 mg / 50 mg

Zeldox 20 mg Norge - norsk - Statens legemiddelverk

zeldox 20 mg

orifarm as - ziprasidonhydrokloridmonohydrat - kapsel, hard - 20 mg

Zeldox 40 mg Norge - norsk - Statens legemiddelverk

zeldox 40 mg

orifarm as - ziprasidonhydrokloridmonohydrat - kapsel, hard - 40 mg

Zeldox 20 mg Norge - norsk - Statens legemiddelverk

zeldox 20 mg

orifarm as - ziprasidonhydrokloridmonohydrat - kapsel, hard - 20 mg

Mekinist Den europeiske union - norsk - EMA (European Medicines Agency)

mekinist

novartis europharm limited - trametinib - melanom - antineoplastiske midler - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. non-small cell lung cancer (nsclc)trametinib i kombinasjon med dabrafenib er indisert for behandling av voksne pasienter med avansert non-small cell lung cancer med en braf v600 mutasjon.

Tafinlar Den europeiske union - norsk - EMA (European Medicines Agency)

tafinlar

novartis europharm limited - dabrafenib mesilate - melanom - antineoplastiske midler - melanomadabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. adjuvant behandling av melanomadabrafenib i kombinasjon med trametinib er indikert for adjuvant behandling av voksne pasienter med stadium iii melanom med en braf v600 mutasjon, følgende komplett reseksjon. non-small cell lung cancer (nsclc)dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.